Inhibition of prostaglandin synthesis by topically applied flurbiprofen in human primary irritant dermatitis

Inhibition of prostaglandin synthesis by topically applied flurbiprofen in human primary irritant dermatitis

The inhibitory effect of topically applied flurbiprofen, a newer nonsteroidal antiinflammatory agent, on prostaglandin biosynthesis in human skin biopsies in primary irritant dermatitis was examined. The flurbiprofen‐treated areas synthesized significantly less PGE1 (279 pg/mg dry weight) than place...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug development research 1981, Vol.1 (1), p.55-58
Hauptverfasser: Kassis, Vibeke, Søndergaard, Jørgen
Format: Artikel
Sprache:eng
Schlagworte:
flurbiprofen
primary irritant dermatitis
prostaglandin E1 biosynthesis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 58
container_issue 1
container_start_page 55
container_title Drug development research
container_volume 1
creator Kassis, Vibeke
Søndergaard, Jørgen
description The inhibitory effect of topically applied flurbiprofen, a newer nonsteroidal antiinflammatory agent, on prostaglandin biosynthesis in human skin biopsies in primary irritant dermatitis was examined. The flurbiprofen‐treated areas synthesized significantly less PGE1 (279 pg/mg dry weight) than placebo‐treated inflamed skin (626 pg/mg dry weight). The average inhibition in 11 treated patients was 55% (P < 0.01 with Wilcoxon's signed rank test). Furthermore the anti‐inflammatory effect of flurbiprofen was clinically evaluated, and a poor correlation was found between the reduction of prostaglandin synthesis and the clinical effects of flurbiprofen.
doi_str_mv 10.1002/ddr.430010107
format Article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_ddr_430010107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DDR430010107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3217-fc5b33b89e35a7eebe5be54efdb900211d686bf78dfcd52001a007e67dbdf92d3</originalsourceid><addsrcrecordid>eNp9kEFLAzEQhYMoWKtH7_kDq8lmd7N7tK22haJYFMVLSDaJjabZkqTo_nsjLcWTzMBcvjcz7wFwidEVRii_ltJfFQQhnIoegQFGTZ3ledMcgwHKaZ4VpMGn4CyEjwThoq4HwM7dyggTTedgp-HGdyHyd8udNA6G3sWVCiZA0cPYbUzLre0h32ysURJqu_XCJIlWDiZ8tV1zl1aYNfc9NN6byF2EUvk1j-lEOAcnmtugLvZzCJ7vbp_Gs2zxMJ2PbxZZS3JMM92WghBRN4qUnColVJm6UFqKJvnEWFZ1JTStpW5lmScvHCGqKiqF1E0uyRBku71tshO80mz_FMOI_UbFUlTsEFXi6Y7_Mlb1_8NsMln-Ve4vmRDV90HJ_SerKKEle7mfstfZ22g0njyyJfkBE6qADA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inhibition of prostaglandin synthesis by topically applied flurbiprofen in human primary irritant dermatitis</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kassis, Vibeke ; Søndergaard, Jørgen</creator><creatorcontrib>Kassis, Vibeke ; Søndergaard, Jørgen</creatorcontrib><description>The inhibitory effect of topically applied flurbiprofen, a newer nonsteroidal antiinflammatory agent, on prostaglandin biosynthesis in human skin biopsies in primary irritant dermatitis was examined. The flurbiprofen‐treated areas synthesized significantly less PGE1 (279 pg/mg dry weight) than placebo‐treated inflamed skin (626 pg/mg dry weight). The average inhibition in 11 treated patients was 55% (P &lt; 0.01 with Wilcoxon's signed rank test). Furthermore the anti‐inflammatory effect of flurbiprofen was clinically evaluated, and a poor correlation was found between the reduction of prostaglandin synthesis and the clinical effects of flurbiprofen.</description><identifier>ISSN: 0272-4391</identifier><identifier>EISSN: 1098-2299</identifier><identifier>DOI: 10.1002/ddr.430010107</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>flurbiprofen ; primary irritant dermatitis ; prostaglandin E1 biosynthesis</subject><ispartof>Drug development research, 1981, Vol.1 (1), p.55-58</ispartof><rights>Copyright © 1981 Alan R. Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3217-fc5b33b89e35a7eebe5be54efdb900211d686bf78dfcd52001a007e67dbdf92d3</citedby><cites>FETCH-LOGICAL-c3217-fc5b33b89e35a7eebe5be54efdb900211d686bf78dfcd52001a007e67dbdf92d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fddr.430010107$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fddr.430010107$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,4022,27922,27923,27924,45573,45574</link.rule.ids></links><search><creatorcontrib>Kassis, Vibeke</creatorcontrib><creatorcontrib>Søndergaard, Jørgen</creatorcontrib><title>Inhibition of prostaglandin synthesis by topically applied flurbiprofen in human primary irritant dermatitis</title><title>Drug development research</title><addtitle>Drug Dev. Res</addtitle><description>The inhibitory effect of topically applied flurbiprofen, a newer nonsteroidal antiinflammatory agent, on prostaglandin biosynthesis in human skin biopsies in primary irritant dermatitis was examined. The flurbiprofen‐treated areas synthesized significantly less PGE1 (279 pg/mg dry weight) than placebo‐treated inflamed skin (626 pg/mg dry weight). The average inhibition in 11 treated patients was 55% (P &lt; 0.01 with Wilcoxon's signed rank test). Furthermore the anti‐inflammatory effect of flurbiprofen was clinically evaluated, and a poor correlation was found between the reduction of prostaglandin synthesis and the clinical effects of flurbiprofen.</description><subject>flurbiprofen</subject><subject>primary irritant dermatitis</subject><subject>prostaglandin E1 biosynthesis</subject><issn>0272-4391</issn><issn>1098-2299</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1981</creationdate><recordtype>article</recordtype><recordid>eNp9kEFLAzEQhYMoWKtH7_kDq8lmd7N7tK22haJYFMVLSDaJjabZkqTo_nsjLcWTzMBcvjcz7wFwidEVRii_ltJfFQQhnIoegQFGTZ3ledMcgwHKaZ4VpMGn4CyEjwThoq4HwM7dyggTTedgp-HGdyHyd8udNA6G3sWVCiZA0cPYbUzLre0h32ysURJqu_XCJIlWDiZ8tV1zl1aYNfc9NN6byF2EUvk1j-lEOAcnmtugLvZzCJ7vbp_Gs2zxMJ2PbxZZS3JMM92WghBRN4qUnColVJm6UFqKJvnEWFZ1JTStpW5lmScvHCGqKiqF1E0uyRBku71tshO80mz_FMOI_UbFUlTsEFXi6Y7_Mlb1_8NsMln-Ve4vmRDV90HJ_SerKKEle7mfstfZ22g0njyyJfkBE6qADA</recordid><startdate>1981</startdate><enddate>1981</enddate><creator>Kassis, Vibeke</creator><creator>Søndergaard, Jørgen</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1981</creationdate><title>Inhibition of prostaglandin synthesis by topically applied flurbiprofen in human primary irritant dermatitis</title><author>Kassis, Vibeke ; Søndergaard, Jørgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3217-fc5b33b89e35a7eebe5be54efdb900211d686bf78dfcd52001a007e67dbdf92d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1981</creationdate><topic>flurbiprofen</topic><topic>primary irritant dermatitis</topic><topic>prostaglandin E1 biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kassis, Vibeke</creatorcontrib><creatorcontrib>Søndergaard, Jørgen</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><jtitle>Drug development research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kassis, Vibeke</au><au>Søndergaard, Jørgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of prostaglandin synthesis by topically applied flurbiprofen in human primary irritant dermatitis</atitle><jtitle>Drug development research</jtitle><addtitle>Drug Dev. Res</addtitle><date>1981</date><risdate>1981</risdate><volume>1</volume><issue>1</issue><spage>55</spage><epage>58</epage><pages>55-58</pages><issn>0272-4391</issn><eissn>1098-2299</eissn><abstract>The inhibitory effect of topically applied flurbiprofen, a newer nonsteroidal antiinflammatory agent, on prostaglandin biosynthesis in human skin biopsies in primary irritant dermatitis was examined. The flurbiprofen‐treated areas synthesized significantly less PGE1 (279 pg/mg dry weight) than placebo‐treated inflamed skin (626 pg/mg dry weight). The average inhibition in 11 treated patients was 55% (P &lt; 0.01 with Wilcoxon's signed rank test). Furthermore the anti‐inflammatory effect of flurbiprofen was clinically evaluated, and a poor correlation was found between the reduction of prostaglandin synthesis and the clinical effects of flurbiprofen.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><doi>10.1002/ddr.430010107</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0272-4391
ispartof Drug development research, 1981, Vol.1 (1), p.55-58
issn 0272-4391
1098-2299
language eng
recordid cdi_crossref_primary_10_1002_ddr_430010107
source Wiley Online Library Journals Frontfile Complete
subjects flurbiprofen
primary irritant dermatitis
prostaglandin E1 biosynthesis
title Inhibition of prostaglandin synthesis by topically applied flurbiprofen in human primary irritant dermatitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T03%3A24%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20prostaglandin%20synthesis%20by%20topically%20applied%20flurbiprofen%20in%20human%20primary%20irritant%20dermatitis&rft.jtitle=Drug%20development%20research&rft.au=Kassis,%20Vibeke&rft.date=1981&rft.volume=1&rft.issue=1&rft.spage=55&rft.epage=58&rft.pages=55-58&rft.issn=0272-4391&rft.eissn=1098-2299&rft_id=info:doi/10.1002/ddr.430010107&rft_dat=%3Cwiley_cross%3EDDR430010107%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true